RedShift BioAnalytics Appoints Amol Chaubal to Board of Directors
Burlington, MA- Sept 7th, 2021 RedShift BioAnalytics (RedShiftBio), a company providing next-generation platform technology enabling measurements of previously undetectable structure changes in biomolecules, announced the appointment of Amol Chaubal to its Board of Directors.
Chaubal is Chief Financial Officer at Waters Corporation, the world’s leading specialty measurement company, which has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences.
“I am thrilled to welcome Amol to our Board of Directors as the company continues to capitalize on the significant market opportunity for our MMS technology and the AQS3 platform,” said Julien Bradley, CEO of RedShiftBio. “Waters has been a significant investor in the company and strong partner over the last several years, and Amol’s financial acumen and industry experience will be invaluable to us in the next phase of our growth.”
Prior to joining Waters, Amol was CFO at Quanterix since 2019. From 2017 to 2019, he was CFO of Global Operations at Smith & Nephew. Prior to his time at Smith & Nephew, Amol served as Corporate Vice President and Head of Finance for PAREXEL’s Clinical Research Services and Access business. He spent 11 years with Novartis in positions of increasing responsibility, including CFO North America – Vaccines & Diagnostics, across Switzerland, Canada and the United States. He began his career with Procter & Gamble. Amol has an MBA from INSEAD (France) and a Master’s in Chemical Engineering from the Indian Institute of Technology, Mumbai.
“I am honored to be appointed to RedShiftBio’s Board of Directors,” said Chaubal. “The company’s technology platform targets a clear need in biophysical characterization that can enable the biopharmaceutical industry to optimize drug development. I’m also pleased to work again with Julien, with whom I worked closely and productively at Quanterix prior to joining Waters.”
“Amol is a great addition to RedShiftBio’s Board.” said Bryson Hollimon, Chairman of the Board of Directors and Managing General Partner at Technology Venture Partners. “His experience and expertise are an excellent complement to our team of Directors and I look forward to working closely with him in support of the company’s significant growth and market opportunity in biotech and biopharma.”
RedShiftBioⓇ is a forward-thinking technology company providing a powerful, life sciences platform for reliable and accurate detection of pivotal changes in molecular structure that affect the critical quality attributes governing the safety, efficacy, and stability of biomolecules and their raw materials The company has developed a powerful new analytical technique, Microfluidic Modulation Spectroscopy (MMS) that provides comprehensive information across five key measurements, in a single automated analysis, replacing the requirement to run samples on multiple instruments. RedShiftBio is headquartered out of Burlington, Massachusetts. For more information, please visit www.redshiftbio.com.